Hydrocortisone Hemisuccinate Anhydrous

Summary

Hydrocortisone Hemisuccinate Anhydrous (CHEMBL977) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 1
• Chemistry: 462.5 Da · C25H34O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL977
Name	Hydrocortisone Hemisuccinate Anhydrous
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	16623
ChEBI	CHEBI:31677
Molecular formula	C25H34O8
Molecular weight	462.5
InChIKey	VWQWXZAWFPZJDA-CGVGKPPMSA-N

SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CCC(=O)O)O)C)O

IUPAC name: 4-[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid

ChEBI definition: A derivative of succinic acid in which one of the carboxy groups is esterified by the C-21 hydroxy group of cortisol (hydrocortisone).

Also known as: Hydrocortisone hemisuccinate anhydrous, NSC-7576, Oristar hcshs, Hydrocortisone hemisuccinate, SID855704, SID56422426, HYDROCORTISONE HEMISUCCINATE, HYDROCORTISONE HEMISUCCINATE ANHYDROUS, C0164806, hydrocortisone succinate

Parent form; salt/anhydrous children: CHEMBL1200495, CHEMBL3989663

Patent coverage: 784 distinct patent families (2,639 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Survival motor neuron protein, Beta-lactamase, Glucocorticoid receptor, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 5 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P06537	6.72	Kd	190	nM	CHEMBL_ACT_14698041
P00811	6.2	Potency	631	nM	CHEMBL_ACT_4630788
HIF1A	6.1	Potency	794.3	nM	CHEMBL_ACT_4127901
HIF1A	6.1	Potency	794.3	nM	CHEMBL_ACT_4520510
SMN1	5.9	Potency	1259	nM	CHEMBL_ACT_3882835

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02768740	PHASE4	COMPLETED	Hydrocortisone 50 mg Every 6 Hours Compared to Hydrocortisone 300 mg Per Day in Treatment of Septic Shock.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).